Focusing on the internationalization of Chinese pharmaceutical formulations, Pharmacare is committed to safeguarding public health worldwide and continuously supplying safe, high-quality and compliant domestic formulations to global markets. The company’s formulation portfolio covers five major categories: blood products, biological products, vaccines, complex generics and orphan drugs, spanning six clinical pipelines including immunology, hematology, oncology, respiratory diseases, anti-infection and endocrinology, featuring comprehensive product coverage and broad market potential.

We maintain in-depth partnerships with leading domestic pharmaceutical manufacturers, all of which hold domestic GMP certifications as well as GMP approvals from major regulated markets including Europe, the United States, Japan and Australia. Taking blood products as an example: Pharmacare has entered into deep strategic cooperation with top domestic blood product manufacturers to jointly explore global markets. At present, blood products are in tight supply across many regions worldwide. Domestic plasma collection capacity will expand steadily in the next 3–5 years, continuously improving the export supply capacity. Meanwhile, our partners are ramping up R&D of new proteins and new varieties to enrich the product pipeline.

Supported by a professional international regulatory registration team proficient in drug authority policies across the globe with proven expertise in CTD dossier compilation, we have finalized nearly a hundred drug registration documents, laying a solid compliance foundation for Chinese formulations going global. With years of dedicated efforts, our products are available in more than 60 countries and regions, and we have obtained over 100 overseas drug registration approvals. Pharmacare is also the first Chinese enterprise to complete generic drug registration and achieve commercialization in Brazil.

Going forward, Pharmacare will continue to advance the global export of domestic pharmaceutical formulations. We will work alongside upstream and downstream partners to share resources and pursue win-win outcomes, further expanding the global reach of high-quality Chinese medicines.